Private Equity Solutions

Protein marker associated with positive outcome in invasive breast cancer

Private Equity Fund Of Funds Researchers at Sunnybrook and Women's College Health Sciences Centre have found a new protein marker linked to positive outcome in patients with breast cancer.

By giving breast cancer to an otherwise healthy, athletic character like Dana, the show makes the point that the disease can strike anyone. Breast cancer is the most common type of cancer among women in the U.S., accounting for 1 of every 3 cancer diagnoses in women. 1 in 9 women in their lifetime get breast cancer. About 211, 000 cases of invasive breast cancer will be diagnosed this year and over 40, 000 women will die from it.

Curve Equity Exposed Fund The research published today in Cancer Research is the first to show that patients with high levels of the protein BCA2 are less likely to experience breast cancer re-occurrence than patients with low levels of BCA2.

Inflammatory Breast Cancer (IBC) Inflammatory breast cancer (IBC) is a rare and aggressive form of invasive breast cancer that is usually not detected by mammograms or ultrasounds. IBC usually grows in nests or sheets rather than as a confined solid tumor and can be diffuse throughout the breast with no palpable mass. The cancer cells clog the lymphatic system just below the skin, resulting in lymph node involvement. Increased breast density compared to prior mammograms should be considered suspicious.

Equity Income Funds "For the first time we have been able to show that the over-expression of BCA2 is a favorable factor in breast cancer in relation to occurrence of lymph node metastases and regional recurrence," says principle investigator Dr. Arun Seth, senior scientist in molecular and cellular biology research at Sunnybrook & Women's. "Higher levels of BCA2 are somewhat protective for regional recurrence."

is wholly owned by Dimensional Associates, Inc., the private equity arm of JDS Capital Management, Inc.

Capital Casebook Equity Testing the effects of BCA2 expression in 1000 invasive breast tumor samples, researchers revealed that BCA2 is associated with the positive estrogen receptor, negative lymph node status and an increase in disease-free survival for regional recurrence.

Studies by Dr. Eddy group have shown that green tea also inhibits a growth factor receptor called HER2, which is present in excess in about 30% of breast cancers and is associated with poor outcomes. Not only does EGCG inhibit growth of breast cancer cells in mice, but in one study it blocked the growth of breast cancer cells taken from a patient who did not respond to treatment with an antibody against HER2. Known as trastuzumab, positive tumors. Unlike trastuzumab, EGCG can enter into the brain, making it potentially useful in patients with breast tumors that have spread to the brain. 51

Private Investment In Public Estrogen receptor (ER) positive invasive breast cancers in general have a better prognosis than ER-negative tumors and are less aggressive. In breast cancer where BCA2 and ER expression are co-regulated BCA2 might provide an alternative target for the treatment of hormone-refractory breast tumors.

The study of 345 women found that the test detected 95 percent of breast cancers, BBC News reported. The blood test developed by American and British researchers detects minor changes in the concentrations of certain proteins in the blood. Some of these proteins are specific for breast tissue, related inflammation and new blood vessel growth. The researchers said that by changing the combination of proteins the test detects, it could be used to spot other kinds of cancers, BBC News reported.

Equity Mutual Funds BCA2, a novel RING type E3 ligase protein discovered by Seth's lab in 2000 and filed for a patent in the US in 2002, has an inherent autoubiquitination activity. Ubiquitin is a small protein that marks other proteins by attaching itself to them and directing them to the proteasome for degradation. The BCA2 mediated such ubiquitin modification of the specific cancer related proteins affect breast cancer progression.

Birmingham Contact Equity "Now that we have determined that higher levels BCA2 are associated with a positive outcome, we are working to determine whether the BCA2 ligase functions as an oncogene in some tissues and as a tumor suppressor in others," says Seth who is also a professor at the University of Toronto. "Targeting the BCA2 mediated breakdown of tumor suppressors could provide a new therapy to block breast tumor growth."

Private Equity Investment Firm The Canada Foundation for Innovation and the Ontario Innovation Trust, now the Ontario Research Fund-Research Infrastructure, funded the infrastructure for this research. The Canadian Institutes of Health Research and the Canadian Breast Cancer Research Alliance provided operating grants.

Complying Deal Equity Funds Sunnybrook and Women's College Health Sciences Centre is transforming health care through the dedication of its more than 10,000 staff members and volunteers. Specializing in women's health programs, caring for Canada's war veterans, conducting leading-edge research, and teaching the latest advances in healthcare through our affiliation with the University of Toronto, distinguishes Sunnybrook & Women's as one of the country's premier academic health sciences centres. Sunnybrook & Women's improves the lives of hundreds of thousands of people each year by caring for newborns, adults and the elderly, treating and preventing cancer, heart and circulation diseases, disorders of the brain, mind and nervous system, orthopaedic and arthritic conditions, and traumatic injuries.

Equity Msn Private Wyoming University of Toronto

[ Comment, Edit or Article Submission ]